Objective REGENERA will assess the technical and commercial feasibility of a novel and optimised C-MANF peptide as a superior treatment for amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease affecting 450,000 people worldwide where motoneurons (MNs) selectively degenerate in the brain and spinal cord. ALS is characterised by muscle deterioration that rapidly leads to disability and culminates in death 3-5 years after diagnosis. Unfortunately, there is no cure for ALS and current treatments only marginally slow down its progression. Moreover, promising neurotrophic factors (NTFs) with neuroprotective activity show insufficient efficiency, are unable to reach the brain tissue, and have highly invasive administration routes (i.e. brain injections and intrathecal) and high production costs. As a result, all NTFs clinical trials have failed. Ass. Prof. Voutilainen has discovered C-MANF, a novel peptide which, in contrast to classical NTFs, (i) has protective and restorative effects on motoneurons, (ii) penetrates the blood-brain barrier (BBB), (iii) can be subcutaneously administered, and (iv) can be inexpensively produced. Within REGENERA, we will assess whether C-MANF is feasible as an early-therapy option for ALS. Firstly, we will analyse the pharmacokinetic properties and efficacy of C-MANF in ALS animal models and in human MNS. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business case to establish the best path to commercialisation. Successful commercialisation of C-MANF could reduce the profound socioeconomic burden of ALS, provide an early-therapy option to delay disease progression and thus extend and improve the patients’ lives, and provide the pharmaceutical industry with a novel therapeutic that can potentially be used for other neurodegenerative diseases. Fields of science natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis Programme(s) HORIZON.1.1 - European Research Council (ERC) Main Programme Topic(s) ERC-2022-POC1 - ERC PROOF OF CONCEPT GRANTS1 Call for proposal ERC-2022-POC1 See other projects for this call Funding Scheme ERC-POC - Proof of Concept Grant Coordinator HELSINGIN YLIOPISTO Net EU contribution € 150 000,00 Address Yliopistonkatu 3 00014 Helsingin yliopisto Finland See on map Region Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data
